Highlights

- **Universal Cells** was acquired by Astellas Pharma for $102.5 million. The transaction accelerates Astellas' research and development in diseases associated with mitochondrial dysfunctions and will enable the delivery of innovative new treatment options to patients.

- **Unna, LLC** raised $100,000 of angel funding in the form of SAFE notes from an undisclosed investor.
### Washington Life Science Transactions 2018

<table>
<thead>
<tr>
<th>Date</th>
<th>Company</th>
<th>Type</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>01/02/18</td>
<td>Kitotech Medical</td>
<td>Equity</td>
<td>$339,000</td>
</tr>
<tr>
<td>01/03/18</td>
<td>Growlife, Inc.</td>
<td>Debt</td>
<td>$1,105,000</td>
</tr>
<tr>
<td>01/03/18</td>
<td>WiseRG</td>
<td>Equity</td>
<td>$19,200,000</td>
</tr>
<tr>
<td>01/03/18</td>
<td>AgEnergy Solutions, LLC</td>
<td>Debt</td>
<td>$1,750,000</td>
</tr>
<tr>
<td>01/04/18</td>
<td>Adaptive Biotechnologies</td>
<td>Corporate</td>
<td>undisclosed</td>
</tr>
<tr>
<td>01/05/18</td>
<td>Vivo-TIL Therapeutics Harvest Direct Enterprises, LLC</td>
<td>Equity</td>
<td>$990,000</td>
</tr>
<tr>
<td>01/05/18</td>
<td>Joylux, Inc.</td>
<td>Equity</td>
<td>$5,000,000</td>
</tr>
<tr>
<td>01/08/18</td>
<td>Silverback Therapeutics</td>
<td>Other</td>
<td>$3,749</td>
</tr>
<tr>
<td>01/08/18</td>
<td>Stratos Genomics, Inc.</td>
<td>Equity</td>
<td>$20,156,456</td>
</tr>
<tr>
<td>01/09/18</td>
<td>ST Phi Therapeutics</td>
<td>Equity</td>
<td>$500,000</td>
</tr>
<tr>
<td>01/10/18</td>
<td>Kv1.3 Therapeutics, Inc.</td>
<td>Debt</td>
<td>$168,182</td>
</tr>
<tr>
<td>01/11/18</td>
<td>Stemgenics, Inc.</td>
<td>Equity</td>
<td>$1,800,000</td>
</tr>
<tr>
<td>01/17/18</td>
<td>Immusoft</td>
<td>Equity</td>
<td>$3,613,029</td>
</tr>
<tr>
<td>01/22/18</td>
<td>Juno Therapeutics, Inc./Celgene</td>
<td>Merger/Acquisition</td>
<td>$9,616,000,000</td>
</tr>
<tr>
<td>01/26/18</td>
<td>Alder Biopharmaceuticals</td>
<td>Equity</td>
<td>$99,999,952</td>
</tr>
<tr>
<td>01/29/18</td>
<td>PreViser</td>
<td>Equity</td>
<td>$3,000,000</td>
</tr>
<tr>
<td>01/31/18</td>
<td>Therapeutics</td>
<td>Merger/Acquisition</td>
<td>$614,000,000</td>
</tr>
<tr>
<td>02/06/18</td>
<td>Unna, LLC</td>
<td>Equity</td>
<td>$100,000</td>
</tr>
<tr>
<td>02/06/18</td>
<td>Feminina Group, Inc.</td>
<td>Debt</td>
<td>$25,000</td>
</tr>
<tr>
<td>02/13/18</td>
<td>Catacore, Corp.</td>
<td>Equity</td>
<td>$25,000</td>
</tr>
<tr>
<td>02/14/18</td>
<td>Astellas/Universal Cells</td>
<td>Merger/Acquisition</td>
<td>$102,500,000</td>
</tr>
<tr>
<td>02/15/18</td>
<td>Luna (IUNU, Inc.)</td>
<td>Debt</td>
<td>$5,000,000</td>
</tr>
<tr>
<td>02/16/18</td>
<td>Growlife, Inc.</td>
<td>Equity</td>
<td>$1,000,000</td>
</tr>
<tr>
<td>02/16/18</td>
<td>Growlife, Inc.</td>
<td>Equity</td>
<td>$321,945</td>
</tr>
<tr>
<td>02/26/18</td>
<td>Carewave</td>
<td>Equity</td>
<td>$150,000</td>
</tr>
<tr>
<td>02/28/18</td>
<td>CytoDyn, Inc.</td>
<td>Equity</td>
<td>$17,643,452</td>
</tr>
</tbody>
</table>

**2018 Total** $10,514,523,265